Cargando…

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Vasin, Andrey V, Stukova, Marina A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119556/ https://www.ncbi.nlm.nih.gov/pubmed/37088097 http://dx.doi.org/10.1016/S1473-3099(23)00189-5

Ejemplares similares

Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
por: Wong, Carlos K H, et al.
Publicado: (2023)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection
por: Widyasari, Kristin, et al.
Publicado: (2023)

Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5–adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients
por: Peled, Yael, et al.
Publicado: (2023)

Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76
por: Singh, Urvashi B., et al.
Publicado: (2023)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
por: Scheaffer, Suzanne M., et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
por: Huiberts, Anne J, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
por: Kirsebom, Freja C M, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant
por: Zhou, Zhongcheng, et al.
Publicado: (2022)

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters
por: Machado, Rafael R. G., et al.
Publicado: (2023)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination
por: Li, Jianhua, et al.
Publicado: (2022)

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
por: Wei, Jia, et al.
Publicado: (2023)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

288. Analysis of serum antibody response as correlates of protection against SARS-CoV-2 infection and the effects of BA.4/5 bivalent booster vaccination
por: Yun Lim, So, et al.
Publicado: (2023)

Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2022)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

A booster with SARS-CoV-2 vaccines: protection against Omicron infection
por: Hu, Yuehong, et al.
Publicado: (2022)

Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients
por: Ovcar, Eugen, et al.
Publicado: (2023)

2337. Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial
por: Bennett, Chijioke, et al.
Publicado: (2023)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
por: Sigal, Alex, et al.
Publicado: (2022)

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
por: Diem, Gabriel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t85qqb860rbvck2vtdqgfo56ra